| Title |
Published on |
Year |
| Association between body composition parameters and treatment-related toxicities in patients with metastatic breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors |
CLINICAL NUTRITION |
2025 |
| Impact of Drug-Drug Interactions on Clinical Outcomes in Metastatic Melanoma Patients Treated With Combined BRAF/MEK Inhibitors: A Real-World Study |
PIGMENT CELL & MELANOMA RESEARCH |
2025 |
| Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study |
THE ONCOLOGIST |
2024 |
| Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments |
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY |
2024 |
| Correction to: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study (npj Breast Cancer, (2024), 10, 1, (58), 10.1038/s41523-024-00657-z) |
NPJ BREAST CANCER |
2024 |
| Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature |
CANCER TREATMENT REVIEWS |
2024 |
| Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach |
CANCER IMMUNOLOGY, IMMUNOTHERAPY |
2023 |
| Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES |
2023 |
| Network approach in liquidomics landscape |
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH |
2023 |
| The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma |
CANCERS |
2023 |
| Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study |
FRONTIERS IN ONCOLOGY |
2023 |
| Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study |
JOURNAL OF THE NATIONAL CANCER INSTITUTE |
2023 |
| Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study |
FRONTIERS IN ONCOLOGY |
2023 |
| Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study |
FRONTIERS IN ONCOLOGY |
2023 |
| Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study |
FRONTIERS IN ONCOLOGY |
2023 |
| Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response |
EBIOMEDICINE |
2022 |
| The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature |
FRONTIERS IN ONCOLOGY |
2022 |
| The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy |
FRONTIERS IN IMMUNOLOGY |
2022 |
| Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer: Potential molecular mechanisms, clinical implications and future perspectives |
CANCERS |
2021 |
| The role of opioids in cancer response to immunotherapy |
JOURNAL OF TRANSLATIONAL MEDICINE |
2021 |
